Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Market opportunity estimated to be greater than US$1 billion
Key highlights
– Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model
– Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS
– Independent Advisory Board supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS
– An Investor Meet Company presentation scheduled at 6pm on 17 January 2024 with Poolbeg management and Key Opinion Leader, Dr Martin Kaiser
17 January 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced CRS.
